Figure 4 | Signal Transduction and Targeted Therapy

Figure 4

From: Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Figure 4

The numbers of CD20+ lymphocyte cells by flow cytometry and the copy numbers of Chimeric Antigen Receptor (CAR) molecules by quantitative real-time-PCR in the peripheral blood of relapsed patients after Chimeric Antigen Receptor-modified T-20 (CART-20) cell infusion. Relapses occurred after the numbers of copies dropped and the numbers of B cells increased. An ↓ indicates the time of relapse.

Back to article page